[Comparative multicenter study of carteolol eyedrops with other beta blockers in 768 patients under normal conditions].
In an open multi-center study involving 768 patients the efficacy and tolerability of Carteolol eye drops as compared to other beta blockers were investigated. The patients started to use the new medication without a prior washout period. In patients who were well stabilized (57%), IOP either did not change when the medication was switched to Carteolol (73%) or it actually decreased. In 78% of the patients who had not responded altogether satisfactorily to the pretreatment, Carteolol eye drops lowered IOP to a tolerable level of 21 mm Hg or less without using any comedication. IOP remained hypertonic under Carteolol in only 19% of the cases. Fewer systemic and local side effects were observed under Carteolol therapy. Patients had fewer problems going upstairs. Burning after installation decreased by 25% to 2%. Even fluorescein-positive corneal findings almost completely disappeared under Carteolol.
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000494:pharmacology; D002354:Carteolol / Q000008:administration & dosage* / Q000494:pharmacology; D004341:Drug Evaluation; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D014290:Metipranolol / Q000008:administration & dosage / Q000494:pharmacology; D009883:Ophthalmic Solutions; D010869:Pindolol / Q000008:administration & dosage / Q000494:pharmacology; D011412:Propanolamines / Q000008:administration & dosage* / Q000494:pharmacology; D013997:Time Factors; D013999:Timolol / Q000008:administration & dosage / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D009883:Ophthalmic Solutions; D011412:Propanolamines; C006034:befunolol; D013999:Timolol; D002354:Carteolol; D010869:Pindolol; D014290:Metipranolol
Vergleichende multizentrische Untersuchung von Carteolol-Augentropfen mit anderen Betablockern bei 768 Patienten unter Alltagsbedingungen.